

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in mice.
The results appear online today in the journal Immunity. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, in collaboration with researchers from Walter Reed Army Institute of Research, led the study.
EBV is one of the most common human viruses. After an EBV infection, the virus becomes dormant in the body but may reactivate in some cases. It is the primary cause of infectious mononucleosis and is associated with certain cancers, including Hodgkin lymphoma, and autoimmune diseases, such as multiple sclerosis.
People with weakened immune systems, such as transplant recipients, are more likely than immunocompetent people to develop severe symptoms and complications from EBV infection. There is no licensed vaccine to protect against the virus.
The researchers developed several investigational mAbs targeting two key proteins—gH and gL—found on EBV’s surface. The two proteins are known to facilitate EBV fusion with human cells and cause infection. When tested in the laboratory setting, the investigational mAbs prevented EBV infection of human B cells and epithelial cells, which line the throat at the initial site of EBV infection.
Analyzing the structure of the mAbs and their two surface proteins using X-ray crystallography and advanced microscopy, the researchers identified multiple sites of vulnerability on the virus to target. When tested in mice, one of the experimental mAbs, called mAb 769B10, provided almost complete protection against Epstein-Barr virus infection when given. The mAb also protected all mice tested from EBV lymphoma.
The findings highlight viable EBV vaccine targets and the potential for the experimental mAbs to be used alone or in combination to prevent or treat EBV infection in immunocompromised patients most susceptible to severe EBV-related disease, according to the researchers. Additional research with mAb 769B10 is planned, the authors note.
more recommended stories
Personalized brain modeling technique may lead to breakthroughs in clinical epilepsy trial
Researchers of the Human Brain Project.
Investigative reporter, who covered murder-suicides, explains how journalists are vulnerable to trauma
It never really dawned on me.
Got gastroenteritis? Here’s why eating bananas helps but drinking flat lemonade might not
Doctors are reportedly concerned about a spike in.
Immunotherapy combined with targeted therapy for colorectal cancer yields promising outcomes for patients
A new study that used insights.
How total abortion ban puts maternal health at risk
Pregnant patients in El Salvador, who,.
Scientists find that microRNA affects inflammation in lupus disease.
A group of researchers from the.
Researchers unveil new collection of human brain atlases that chart postnatal development
Human brain atlases can be used.
New hope for patients with hereditary metabolic disorder
Methylmalonic aciduria (MMA) is a metabolic.
Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
A new study that analyzed the.
Study shows correlation between poor sleep and suicide risk in college-aged adults
A study led by researchers in.
Leave a Comment